All Eyes On US Approval After Ipsen’s FOP Candidate Rejected By EU
Second Time Lucky?
The French firm’s palovarotene for fibrodysplasia ossificans progressiva received a thumbs down from the European Commission, but a positive advisory committee outcome on the other side of the pond bodes well for its second attempt at US approval.
